All
FDA Approves Leukine to Treat Blood-Related Acute Radiation Syndrome
June 6th 2018The Food and Drug Administration (FDA) approved Leukine (sargramostim) for the treatment of adult and pediatric patients who are exposed to myelosuppressive doses of radiation that results in a hematopoietic subsyndrome of acute radiation syndrome.
FDA Approves First Biosimilar to Reduce Risk of Infection During Cancer Treatment
June 5th 2018The Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to reduce the risk for febrile neutropenia in patients treated with chemotherapy in certain types of cancer.
Sound Affects Seeks to Change Fight, Finances of War on Cancer
June 1st 2018While many advocacy groups set out to raise money for cancer research, a first-of-its-kind charitable crowdfunding platform, called Sound Affects, has set out to change how the war on cancer is fought and financed, all with support from musical talents.
By Taking Survey, Those With Breast Cancer Can Help Pink Fund Offer Financial Resources
June 1st 2018The group is seeking 1,000 people, diagnosed with breast cancer before the age of 40, to complete an online survey about how the journey affected them financially. The survey will support the organization’s efforts to bring more benefits to patients in need.
Patient Legacy Lives On Thanks to Music Industry Help
May 31st 2018Fueled by the tragic loss of their son, Tony and his wife Vicky Martell built the foundation by working closely with their passionate friends in the music industry to continue his legacy and expand the foundation’s fundraising initiatives every year.
FDA Grants Gilteritinib a Priority Review for Acute Myeloid Leukemia Treatment
May 29th 2018The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML), according to Astellas Pharma, the manufacturer of the FLT3 inhibitor.
Larotrectinib Granted Priority Review for NTRK-Positive Cancers
May 29th 2018The FDA has granted a priority review to a new drug application (NDA) for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor.